These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 35169798)

  • 21. mRNA Booster Vaccination Enhances Antibody Responses against SARS-CoV2 Omicron Variant in Individuals Primed with mRNA or Inactivated Virus Vaccines.
    Zhang B; Huo J; Huang Y; Teo SY; Duan K; Li Y; Toh LK; Lam KP; Xu S
    Vaccines (Basel); 2022 Jun; 10(7):. PubMed ID: 35891221
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neutralizing antibodies to SARS-CoV-2 variants of concern including Delta and Omicron in subjects receiving mRNA-1273, BNT162b2, and Ad26.COV2.S vaccines.
    Zhang GF; Meng W; Chen L; Ding L; Feng J; Perez J; Ali A; Sun S; Liu Z; Huang Y; Guo H; Gao SJ
    J Med Virol; 2022 Dec; 94(12):5678-5690. PubMed ID: 35902378
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variant.
    Lyke KE; Atmar RL; Islas CD; Posavad CM; Szydlo D; Paul Chourdhury R; Deming ME; Eaton A; Jackson LA; Branche AR; El Sahly HM; Rostad CA; Martin JM; Johnston C; Rupp RE; Mulligan MJ; Brady RC; Frenck RW; Bäcker M; Kottkamp AC; Babu TM; Rajakumar K; Edupuganti S; Dobrzynski D; Coler RN; Archer JI; Crandon S; Zemanek JA; Brown ER; Neuzil KM; Stephens DS; Post DJ; Nayak SU; Suthar MS; Roberts PC; Beigel JH; Montefiori DC;
    Cell Rep Med; 2022 Jul; 3(7):100679. PubMed ID: 35798000
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Loss of Pfizer (BNT162b2) Vaccine-Induced Antibody Responses against the SARS-CoV-2 Omicron Variant in Adolescents and Adults.
    Gupta SL; Mantus G; Manning KE; Ellis M; Patel M; Ciric CR; Lu A; Turner JS; O'Halloran JA; Presti RM; Joshi DJ; Ellebedy AH; Anderson EJ; Rostad CA; Suthar MS; Wrammert J
    J Virol; 2022 Sep; 96(17):e0058222. PubMed ID: 35976000
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Single Ad26.COV2.S booster dose following two doses of BBIBP-CorV vaccine against SARS-CoV-2 infection in adults: Day 28 results of a phase 1/2 open-label trial.
    Muangnoicharoen S; Wiangcharoen R; Nanthapisal S; Kamolratakul S; Lawpoolsri S; Jongkaewwattana A; Thitithanyanont A; Luvira V; Chinwangso P; Thanthamnu N; Chantratita N; Lim JK; Anh Wartel T; Excler JL; Ryser MF; Leong C; Mak TK; Pitisuttithum P
    Vaccine; 2023 Jul; 41(32):4648-4657. PubMed ID: 37344265
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and immunogenicity of booster vaccination and fractional dosing with Ad26.COV2.S or BNT162b2 in Ad26.COV2.S-vaccinated participants.
    Riou C; Bhiman JN; Ganga Y; Sawry S; Ayres F; Baguma R; Balla SR; Benede N; Bernstein M; Besethi AS; Cele S; Crowther C; Dhar M; Geyer S; Gill K; Grifoni A; Hermanus T; Kaldine H; Keeton RS; Kgagudi P; Khan K; Lazarus E; Le Roux J; Lustig G; Madzivhandila M; Magugu SFJ; Makhado Z; Manamela NP; Mkhize Q; Mosala P; Motlou TP; Mutavhatsindi H; Mzindle NB; Nana A; Nesamari R; Ngomti A; Nkayi AA; Nkosi TP; Omondi MA; Panchia R; Patel F; Sette A; Singh U; van Graan S; Venter EM; Walters A; Moyo-Gwete T; Richardson SI; Garrett N; Rees H; Bekker LG; Gray G; Burgers WA; Sigal A; Moore PL; Fairlie L
    PLOS Glob Public Health; 2024; 4(4):e0002703. PubMed ID: 38603677
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and immunogenicity of booster vaccination and fractional dosing with Ad26.COV2.S or BNT162b2 in Ad26.COV2.S-vaccinated participants.
    Riou C; Bhiman JN; Ganga Y; Sawry S; Ayres F; Baguma R; Balla SR; Benede N; Bernstein M; Besethi AS; Cele S; Crowther C; Dhar M; Geyer S; Gill K; Grifoni A; Hermanus T; Kaldine H; Keeton RS; Kgagudi P; Khan K; Lazarus E; Roux JL; Lustig G; Madzivhandila M; Magugu SF; Makhado Z; Manamela NP; Mkhize Q; Mosala P; Motlou TP; Mutavhatsindi H; Mzindle NB; Nana A; Nesamari R; Ngomti A; Nkayi AA; Nkosi TP; Omondi MA; Panchia R; Patel F; Sette A; Singh U; van Graan S; Venter EM; Walters A; Moyo-Gwete T; Richardson SI; Garrett N; Rees H; Bekker LG; Gray G; Burgers WA; Sigal A; Moore PL; Fairlie L
    medRxiv; 2023 Nov; ():. PubMed ID: 38045321
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differential immunogenicity of homologous versus heterologous boost in Ad26.COV2.S vaccine recipients.
    Khoo NKH; Lim JME; Gill US; de Alwis R; Tan N; Toh JZN; Abbott JE; Usai C; Ooi EE; Low JGH; Le Bert N; Kennedy PTF; Bertoletti A
    Med; 2022 Feb; 3(2):104-118.e4. PubMed ID: 35072129
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Booster vaccination with Ad26.COV2.S or an Omicron-adapted vaccine in pre-immune hamsters protects against Omicron BA.2.
    Swart M; van der Lubbe J; Schmit-Tillemans S; van Huizen E; Verspuij J; Gil AI; Choi Y; Daal C; Perkasa A; de Wilde A; Claassen E; de Jong R; Wiese KE; Cornelissen L; van Es M; van Heerden M; Kourkouta E; Tahiri I; Mulders M; Vreugdenhil J; Feddes-de Boer K; Muchene L; Tolboom J; Dekking L; Juraszek J; Vellinga J; Custers J; Bos R; Schuitemaker H; Wegmann F; Roozendaal R; Kuipers H; Zahn R
    NPJ Vaccines; 2023 Mar; 8(1):40. PubMed ID: 36927774
    [TBL] [Abstract][Full Text] [Related]  

  • 30. SARS-CoV2 variant-specific replicating RNA vaccines protect from disease following challenge with heterologous variants of concern.
    Hawman DW; Meade-White K; Archer J; Leventhal SS; Wilson D; Shaia C; Randall S; Khandhar AP; Krieger K; Hsiang TY; Gale M; Berglund P; Fuller DH; Feldmann H; Erasmus JH
    Elife; 2022 Feb; 11():. PubMed ID: 35191378
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Boosting with Multiple Doses of mRNA Vaccine after Priming with Two Doses of Protein Subunit Vaccine MVC-COV1901 Elicited Robust Humoral and Cellular Immune Responses against Emerging SARS-CoV-2 Variants.
    Chiu CH; Chang YH; Tao CW; Chang FY; Chiu KC; Chang TW; Yen LC
    Microbiol Spectr; 2022 Oct; 10(5):e0060922. PubMed ID: 36005765
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Omicron BA.1-specific T-cell responses in adults vaccinated with CoronaVac or BNT162b2 in Hong Kong: an observational cohort study.
    Mok CKP; Chen C; Zhao S; Sun Y; Yiu K; Chan TO; Lai HL; Lai KC; Lau KM; Ling KC; Chan KKP; Ng SS; Ko FW; Peiris M; Hui DS
    Lancet Microbe; 2023 Jun; 4(6):e418-e430. PubMed ID: 37086735
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and immunogenicity of the protein-based PHH-1V compared to BNT162b2 as a heterologous SARS-CoV-2 booster vaccine in adults vaccinated against COVID-19: a multicentre, randomised, double-blind, non-inferiority phase IIb trial.
    Corominas J; Garriga C; Prenafeta A; Moros A; Cañete M; Barreiro A; González-González L; Madrenas L; Güell I; Clotet B; Izquierdo-Useros N; Raïch-Regué D; Gallemí M; Blanco J; Pradenas E; Trinité B; Prado JG; Blanch-Lombarte O; Pérez-Caballero R; Plana M; Esteban I; Pastor-Quiñones C; Núñez-Costa X; Taleb RA; McSkimming P; Soriano A; Nava J; Anagua JO; Ramos R; Lluch RM; Comes AC; Romero SO; Gomez XM; Sans-Pola C; Moltó J; Benet S; Bailón L; Arribas JR; Borobia AM; Parada JQ; Navarro-Pérez J; Forner Giner MJ; Lucas RO; Jiménez MDMV; Compán SO; Alvarez-Mon M; Troncoso D; Arana-Arri E; Meijide S; Imaz-Ayo N; García PM; de la Villa Martínez S; Fernández SR; Prat T; Torroella È; Ferrer L
    Lancet Reg Health Eur; 2023 May; 28():100613. PubMed ID: 37131861
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prototype and BA.5 protein nanoparticle vaccines protect against Omicron BA.5 variant in Syrian hamsters.
    Bricker TL; Joshi A; Soudani N; Scheaffer SM; Patel N; Guebre-Xabier M; Smith G; Diamond MS; Boon ACM
    J Virol; 2024 Mar; 98(3):e0120623. PubMed ID: 38305154
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunogenicity, durability, and safety of an mRNA and three platform-based COVID-19 vaccines as a third dose following two doses of CoronaVac in China: A randomised, double-blinded, placebo-controlled, phase 2 trial.
    Zhang Y; Ma X; Yan G; Wu Y; Chen Y; Zhou Z; Wan N; Su W; Liu FW; Dai MX; Yang M; Li C; Yu X; Zhang L; Wang Z; Zhou TC; You D; Wei J; Zhang Z;
    EClinicalMedicine; 2022 Dec; 54():101680. PubMed ID: 36188435
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vaccines elicit highly conserved cellular immunity to SARS-CoV-2 Omicron.
    Liu J; Chandrashekar A; Sellers D; Barrett J; Jacob-Dolan C; Lifton M; McMahan K; Sciacca M; VanWyk H; Wu C; Yu J; Collier AY; Barouch DH
    Nature; 2022 Mar; 603(7901):493-496. PubMed ID: 35102312
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Persistent T cell-mediated immune responses against Omicron variants after the third COVID-19 mRNA vaccine dose.
    Belik M; Liedes O; Vara S; Haveri A; Pöysti S; Kolehmainen P; Maljanen S; Huttunen M; Reinholm A; Lundberg R; Skön M; Österlund P; Melin M; Hänninen A; Hurme A; Ivaska L; Tähtinen PA; Lempainen J; Kakkola L; Jalkanen P; Julkunen I
    Front Immunol; 2023; 14():1099246. PubMed ID: 36756112
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MVA-based vaccine candidates expressing SARS-CoV-2 prefusion-stabilized spike proteins of the Wuhan, Beta or Omicron BA.1 variants protect transgenic K18-hACE2 mice against Omicron infection and elicit robust and broad specific humoral and cellular immune responses.
    Pérez P; Astorgano D; Albericio G; Flores S; Sánchez-Corzo C; Noriega MA; Sánchez-Cordón PJ; Labiod N; Delgado R; Casasnovas JM; Esteban M; García-Arriaza J
    Front Immunol; 2024; 15():1420304. PubMed ID: 39267752
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A mosaic-type trimeric RBD-based COVID-19 vaccine candidate induces potent neutralization against Omicron and other SARS-CoV-2 variants.
    Zhang J; Han ZB; Liang Y; Zhang XF; Jin YQ; Du LF; Shao S; Wang H; Hou JW; Xu K; Lei W; Lei ZH; Liu ZM; Zhang J; Hou YN; Liu N; Shen FJ; Wu JJ; Zheng X; Li XY; Li X; Huang WJ; Wu GZ; Su JG; Li QM
    Elife; 2022 Aug; 11():. PubMed ID: 36004719
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Kinetics of cellular and humoral responses to third BNT162B2 COVID-19 vaccine over six months in heart transplant recipients - implications for the omicron variant.
    Peled Y; Afek A; Kreiss Y; Rahav G; Nemet I; Kliker L; Indenbaum V; Ram E; Lavee J; Segev A; Matezki S; Sternik L; Raanani E; Lustig Y; Patel JK; Mandelboim M
    J Heart Lung Transplant; 2022 Oct; 41(10):1417-1425. PubMed ID: 35710484
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.